Clinical trials: aldesleukin
Kidney Cancer
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients with stage III or stage IV kidney cancer…
- Trial name
- NCT00003604
- Testing
- aldesleukin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Cancer Biotherapy Research Group
Solid Tumor
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid tumor and to find appropriate dose for…
- Trial name
- NCT04862767
- Testing
- TASO-001((TGF-β2 targeting anti-sense oligonucleotide), Aldesleukin
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Autotelicbio
Solid Tumor
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor .
- Trial name
- NCT03891706
- Testing
- tumor-specific TCR-T cells, Interleukin-2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Lymphoma
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Donor white blood cells that are treated in the laboratory with Epstein-Barr virus may be effective treatment…
- Trial name
- NCT00006100
- Testing
- aldesleukin, allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes, fludarabine phosphate
- Where
- United States
- Sponsor
- Milton S. Hershey Medical Center
Metastatic Melanoma, Pulmonary Metastases
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of hypofractionated palliative radiation therapy…
- Conditions
- Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
- Trial name
- NCT03297463
- Testing
- Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II)
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lupus Erythematosus, Systemic
Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease with multifactorial genesis. Recent research suggests a numerical and functional deficit of regulatory T (Treg) cells as an important contributing factor to the…
- Trial name
- Charact-IL-2 (NCT03312335)
- Testing
- Low-dose Aldesleukin (Proleukin®)
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Onur Boyman, MD
HIV-1 Infection
Novel Interventions in HIV-1 Infection
For several years there has been interest in why some people with HIV-1 progress more slowly to disease and have longer survival without Highly Active Antiretroviral Therapy (HAART) than others.
- Trial name
- IMIRC1003 (NCT01130376)
- Testing
- GTU-MultiHIV B clade vaccine1mg, Interleukin-2, GM-CSF
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Imperial College London
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Previous research has demonstrated that investigators can coat (arm) T cells with a special molecule called GD2 bispecific antibody that will help T cells recognize neuroblastoma and osteosarcoma cells and kill them.
- Trial name
- NCT02173093
- Testing
- IL-2, GD2Bi-aATC, GM-CSF
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Recurrent Melanoma, Stage IV Melanoma
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
This phase I trial studies the side effects and best dose of autologous T-antigen-presenting cells (T-APC) vaccine following therapeutic autologous lymphocytes (CTL) and cyclophosphamide in treating patients with metastatic…
- Trial name
- NCT01339663
- Testing
- cyclophosphamide, aldesleukin, autologous tumor cell vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
The purpose of this study is to evaluate the safety and tolerability of giving IL-2 plus anti-HIV (antiretroviral) therapy to HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) of at…
- Trial name
- NCT00000825
- Testing
- Aldesleukin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Recurrent Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
This phase I/II trial studies the side effects and best way to give laboratory treated autologous T cells together with aldesleukin and to see how well it works in treating patients with merkel cell carcinoma that has spread from…
- Trial name
- NCT01758458
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fred Hutchinson Cancer Center
Neuroblastoma
Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill neuroblastoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating children with stage IV neuroblastoma who have…
- Trial name
- NCT00003743
- Testing
- aldesleukin
- Where
- Austria
- Volunteers
- 25 people
- Sponsor
- St. Anna Kinderkrebsforschung
Nephrotic Syndrome
IL-2 for Multi Drug Resistant Nephrotic Syndrome
The aim of the study is to design an open-label phase 1-2 trial to assess safety and clinical and immunologic effects of repeated administration of recombinant low dose IL2 (Proleukin) in 5 patients with idiopathic nephrotic…
- Trial name
- NCT02455908
- Testing
- Proleukin®
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Istituto Giannina Gaslini
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer, Breast Cancer
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1.
- Conditions
- Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
- Trial name
- NCT05483491
- Testing
- KK-LC-1 TCR-T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Christian Hinrichs
Papillomavirus Infections, Cervical Intraepithelial Neoplasia
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms
- Trial name
- NCT02858310
- Testing
- E7 TCR cells, Aldesleukin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Skin Cancer, Melanoma
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
Background: Human peripheral blood lymphocytes have been engineered to express a T-cell receptor (TCR) that recognizes a blood type, human leukocyte antigen (HLA-A*0201) derived from the gp100 protein.
- Trial name
- NCT00509496
- Testing
- fludarabine phosphate, cyclophosphamide, aldesleukin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
Background: Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The cells are changed with a virus to attack tumor cells, then returned to the person.
- Trial name
- NCT03354390
- Testing
- cell infusion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV Infections
A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection
The purpose of this study is to look at the effectiveness of combination anti-HIV drug therapy (with protease inhibitors [PIs] or without) in patients with early HIV infections.
- Trial name
- NCT00006154
- Testing
- Indinavir sulfate, Ritonavir, Abacavir sulfate
- Where
- 4 sites in Canada
- Volunteers
- 165 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Melanoma, Skin Cancer
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Background: Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. An experimental procedure developed for treating patients with melanoma uses the anti-MART-1 F5 gene and a type of virus to make…
- Trial name
- NCT00612222
- Testing
- autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)